• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

Recent Advances in the Study of Methyl 3,5-Dihydroxy-4-methylbenzoate (CAS: 75238-29-8)

Methyl 3,5-Dihydroxy-4-methylbenzoate (CAS: 75238-29-8) has recently gained significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound, a methyl ester derivative of 3,5-dihydroxy-4-methylbenzoic acid, has been the subject of several cutting-edge studies exploring its biological activities, synthetic pathways, and pharmacological potential. The current research landscape reveals promising developments in understanding this molecule's role in drug discovery and development.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial properties of Methyl 3,5-Dihydroxy-4-methylbenzoate against drug-resistant bacterial strains. The research team demonstrated that this compound exhibits significant inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) with an MIC value of 8 μg/mL. Structural-activity relationship (SAR) analysis suggested that both the hydroxyl groups and the methyl ester moiety are crucial for this antibacterial activity, providing valuable insights for future antibiotic development.

In the field of oncology, recent preclinical studies have explored the compound's potential as an anticancer agent. Research published in Bioorganic & Medicinal Chemistry Letters (2024) revealed that Methyl 3,5-Dihydroxy-4-methylbenzoate shows selective cytotoxicity against certain cancer cell lines, particularly in breast cancer models (MCF-7 cells). The proposed mechanism involves the inhibition of key signaling pathways, including the PI3K/AKT cascade, although further validation is required to fully elucidate its mode of action.

The synthetic chemistry community has also made notable progress in developing more efficient routes for producing Methyl 3,5-Dihydroxy-4-methylbenzoate. A recent patent application (WO2023/154672) describes an improved synthetic method using biocatalytic methylation, which offers higher yields (up to 85%) and better environmental sustainability compared to traditional chemical synthesis approaches. This advancement could facilitate larger-scale production for research and potential clinical applications.

Pharmacokinetic studies have begun to address the compound's ADME (Absorption, Distribution, Metabolism, and Excretion) properties. Preliminary data from animal models indicate reasonable oral bioavailability (approximately 45%) and favorable tissue distribution patterns, particularly in the liver and kidneys. However, researchers note that metabolic stability remains a challenge, with rapid glucuronidation observed in in vitro hepatic microsome assays.

Looking forward, the most promising research directions for Methyl 3,5-Dihydroxy-4-methylbenzoate appear to be in the areas of infectious disease treatment and cancer therapy. Several research groups are currently investigating structural analogs to optimize both potency and pharmacokinetic properties. The compound's relatively simple structure and the growing understanding of its biological activities make it an attractive scaffold for further medicinal chemistry optimization.

It's worth noting that while the current research on Methyl 3,5-Dihydroxy-4-methylbenzoate is promising, most studies remain at the preclinical stage. Significant work is still needed to fully characterize its safety profile, potential off-target effects, and therapeutic window before clinical translation can be considered. Nevertheless, the compound represents an interesting case study in how simple phenolic derivatives can yield significant biological activities with potential pharmaceutical applications.

• 2150-46-1(Methyl 2,5-dihydroxybenzoate)
• 3147-39-5(Methyl 2,4,6-trihydroxybenzoate)
• 33662-58-7(Benzoic acid,2,4-dihydroxy-3-methyl-, methyl ester)
• 2150-47-2(Methyl 2,4-dihydroxybenzoate)
• 4670-56-8(Methyl 4-Methylsalicylate)
• 3556-86-3(Methyl 4-Methyl-3-hydroxybenzoate)
• 16846-10-9(Methyl 2,6-dihydroxy-4-methylbenzoate)
• 2150-45-0(Methyl 2,6-dihydroxybenzoate)
• 29602-00-4(1,4-Benzenedicarboxylicacid, 2-hydroxy-, 4-methyl ester)
• 6342-72-9(Dimethyl 2-hydroxyterephthalate)